Project Grant HT94252510049
Award Date
1/1/25
Completion Date
12/31/25
Dollars Obligated
$188K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90024, USA
Similar Awards
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $557,438 project grant to the University of California, Los Angeles (UCLA) to investigate UCHL1 as a novel minimally invasive molecular indicator and therapeutic target for small cell lung cancer. This 2-year research project runs from September 15, 2023 to September 14, 2025 and will be conducted through UCLA's Office of Research Administration division. As a prime grantee, UCLA has also...
The University of California, Los Angeles (UCLA) was awarded a $964,477 Project Grant by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant, titled "TARGETING THE RAL G PROTEINS TO TREAT TRIPLE-NEGATIVE BREAST CANCER", will fund advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the public. The 3-year award, effective July 1, 2025 through June 30, 2028, supports innovative...
The Defense Health Agency awarded a $828,591 Project Grant under CFDA 12.420, the Military Medical Research and Development program, to Duke University. The grant supports research titled "Targeting the Tumor Microenvironment to Enhance Immunotherapy for SCLC", with a performance period from May 1, 2025 to April 30, 2027. This research aims to transform healthcare for military service members, veterans, and the public by advancing innovative biomedical investigations focused on...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $630,000.00 to the University of California, Los Angeles (UCLA) for intravesical nectin4 chimeric antigen receptor T cell therapy research for non-muscle invasive bladder cancer. The award period runs from September 1, 2024 to August 31, 2026. As the prime awardee, UCLA will leverage its facilities, faculty expertise, and administrative capabilities...
The University of California Irvine received a $156,998 project grant award from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will support the development of personalized therapeutic cancer vaccines to effectively mobilize antitumor T-cell immunity in non-small cell lung cancer from September 30, 2021 through September 29, 2023. As the sub-awardee, the State of California Controllers Office will...
The Defense Health Agency has awarded a $893,000 Project Grant to the University of California, Los Angeles (UCLA) - Office of Research Administration to conduct research under the Military Medical Research and Development program (CFDA 12.420). This four-year grant, effective August 15, 2023 through August 14, 2027, will support UCLA's efforts to investigate the EGFR signaling network in glioblastoma, an aggressive form of brain cancer. As the prime grantee, UCLA will leverage its research...
This federal Project Grant award, valued at $2,520,000.00, was issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. The primary awardee, the University of California, Los Angeles (UCLA), will leverage its extensive facilities, diverse faculty expertise, and robust administrative capabilities...
This $762,992 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by the University of Texas MD Anderson Cancer Center to map and predict therapy resistance in small cell lung cancer (SCLC) using liquid biopsies. The 3-year award, effective July 1, 2024, will enable MD Anderson to conduct personalized analyses to better understand how SCLC tumors evolve and become resistant to treatment. This work aims to...
The Department of the Army Medical Command awarded a $157,500 Project Grant to The Washington University under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from June 1, 2021 to May 31, 2022 to restore functional ARF tumor suppression in non-small cell lung carcinoma through the use of peptide mimics. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming...
The federal Project Grant award of $1,214,375.00 from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), is funding a research project led by Yale University. The project is investigating the use of decoy-resistant IL-18 and immune checkpoint inhibitors in preclinical murine and ex vivo patient-derived models of renal cell carcinoma. The award began on September 15, 2024 and is set to conclude on September 14, 2028. The Military Medical Research...